Russell Investments Group Ltd. Purchases 663,778 Shares of Augmedix, Inc. (NASDAQ:AUGX)

Russell Investments Group Ltd. raised its holdings in shares of Augmedix, Inc. (NASDAQ:AUGX) by 292.0% during the fourth quarter, Holdings Channel reports. The fund owned 891,077 shares of the company’s stock after buying an additional 663,778 shares during the period. Russell Investments Group Ltd.’s holdings in Augmedix were worth $5,213,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the business. Perkins Capital Management Inc. grew its holdings in shares of Augmedix by 5.3% during the 4th quarter. Perkins Capital Management Inc. now owns 1,464,568 shares of the company’s stock valued at $8,568,000 after purchasing an additional 73,475 shares during the last quarter. Essex Investment Management Co. LLC bought a new position in shares of Augmedix during the third quarter valued at about $2,237,000. Vontobel Holding Ltd. grew its stake in shares of Augmedix by 9.0% during the fourth quarter. Vontobel Holding Ltd. now owns 188,815 shares of the company’s stock valued at $1,105,000 after buying an additional 15,606 shares during the last quarter. Calamos Advisors LLC purchased a new position in shares of Augmedix in the fourth quarter worth about $886,000. Finally, Citigroup Inc. bought a new stake in shares of Augmedix in the 3rd quarter valued at about $241,000. 87.11% of the stock is owned by hedge funds and other institutional investors.

Augmedix Price Performance

Shares of AUGX stock opened at $2.50 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 2.41 and a current ratio of 2.41. Augmedix, Inc. has a fifty-two week low of $2.46 and a fifty-two week high of $6.25. The firm has a market cap of $122.18 million, a P/E ratio of -5.54 and a beta of 0.03. The business’s 50 day moving average price is $3.52 and its 200-day moving average price is $4.52.

Augmedix (NASDAQ:AUGX) last released its quarterly earnings results on Monday, March 18th. The company reported ($0.09) earnings per share for the quarter. The company had revenue of $12.68 million during the quarter, compared to the consensus estimate of $12.30 million. Augmedix had a negative net margin of 42.74% and a negative return on equity of 308.50%. On average, equities research analysts anticipate that Augmedix, Inc. will post -0.51 earnings per share for the current year.

Insider Activity at Augmedix

In related news, insider Ian Shakil sold 58,978 shares of the stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $3.91, for a total value of $230,603.98. Following the completion of the transaction, the insider now directly owns 180,034 shares in the company, valued at approximately $703,932.94. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have sold 251,323 shares of company stock worth $1,005,527 over the last ninety days. 10.97% of the stock is owned by corporate insiders.

Analyst Ratings Changes

AUGX has been the topic of a number of analyst reports. Evercore ISI raised Augmedix from an “in-line” rating to an “outperform” rating and lifted their price target for the stock from $4.50 to $5.00 in a research note on Tuesday, April 9th. B. Riley started coverage on shares of Augmedix in a report on Wednesday, April 3rd. They set a “buy” rating and a $5.50 price target for the company. Finally, Maxim Group cut their price target on shares of Augmedix from $6.50 to $5.00 and set a “buy” rating on the stock in a report on Tuesday, March 19th.

About Augmedix

Augmedix, Inc provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live that provides synchronous medical note documentation and point of care support; Augmedix Go Assist that offers asynchronous medical documentation based upon previously recorded visits; Augmedix Prep that provides patient demographics, past medical history, medication changes and other points from the patient's health record; and Augmedix Go, an autonomous, ambient AI mobile software application that offers fully automated medical documentation based upon recorded visits.